ISL
MYGN icon

Ingalls & Snyder LLC’s Myriad Genetics MYGN Stock Holding History

Ingalls & Snyder LLC’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,185
Closed -$189K – 427
2020
Q1 		$189K Sell
13,185
-14,669
-53% -$310K 0.01% 370
2019
Q4 		$758K Sell
27,854
-18,075
-39% -$497K 0.04% 226
2019
Q3 		$1.31M Sell
45,929
-3,814
-8% -$111K 0.06% 188
2019
Q2 		$1.38M Sell
49,743
-3
-0% -$85 0.07% 189
2019
Q1 		$1.65M Buy
49,746
+220
+0.4% +$6.7K 0.08% 174
2018
Q4 		$1.44M Buy
49,526
+605
+1% +$21.8K 0.08% 174
2018
Q3 		$2.25M Sell
48,921
-125
-0.3% -$5.56K 0.09% 156
2018
Q2 		$1.83M Sell
49,046
-53
-0.1% -$1.79K 0.09% 155
2018
Q1 		$1.45M Hold
49,099
– – 0.07% 173
2017
Q4 		$1.69M Sell
49,099
-4,500
-8% -$152K 0.08% 168
2017
Q3 		$1.94M Buy
53,599
+350
+0.7% +$9.98K 0.1% 137
2017
Q2 		$1.38M Sell
53,249
-975
-2% -$20.7K 0.07% 163
2017
Q1 		$1.04M Sell
54,224
-5,860
-10% -$104K 0.06% 193
2016
Q4 		$1M Sell
60,084
-44,987
-43% -$814K 0.05% 194
2016
Q3 		$2.16M Sell
105,071
-31,941
-23% -$810K 0.12% 130
2016
Q2 		$4.19M Buy
137,012
+777
+0.6% +$27K 0.25% 79
2016
Q1 		$5.1M Sell
136,235
-5,151
-4% -$194K 0.32% 60
2015
Q4 		$6.1M Sell
141,386
-3,110
-2% -$131K 0.39% 56
2015
Q3 		$5.42M Buy
144,496
+6,936
+5% +$246K 0.35% 59
2015
Q2 		$4.67M Sell
137,560
-6,208
-4% -$211K 0.26% 74
2015
Q1 		$5.09M Buy
143,768
+2,724
+2% +$97.5K 0.28% 69
2014
Q4 		$4.8M Sell
141,044
-655
-0.5% -$23.2K 0.28% 70
2014
Q3 		$5.46M Buy
141,699
+1,394
+1% +$52K 0.29% 67
2014
Q2 		$5.46M Buy
140,305
+4,113
+3% +$153K 0.27% 72
2014
Q1 		$4.66M Sell
136,192
-8,112
-6% -$251K 0.25% 76
2013
Q4 		$3.03M Sell
144,304
-18,231
-11% -$461K 0.17% 98
2013
Q3 		$3.82M Buy
162,535
+24,126
+17% +$685K 0.23% 79
2013
Q2 		$3.72M Buy
+138,409
New +$4.01M 0.24% 77

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ingalls & Snyder LLC's MYGN Position: Q2 2020 in Review

Ingalls & Snyder LLC sold out of Myriad Genetics (MYGN) in Q2 2020, closing a stake of 13,185 shares — an estimated $189K sold.

Ingalls & Snyder LLC first reported a position in MYGN in Q2 2013 and held it in 28 quarters. The position peaked at $6.1M in Q4 2015. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2020.

  • Ingalls & Snyder LLC reported no remaining Myriad Genetics position as of Q2 2020 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 13,185 Myriad Genetics shares in Q2 2020, an estimated $189K.
  • Ingalls & Snyder LLC first reported a position in Myriad Genetics in Q2 2013 and held it in 28 quarters.
  • Ingalls & Snyder LLC's Myriad Genetics position peaked at $6.1M in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2020.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2020, filed 31 Jul 2020.